Charlotte Fribert

Company: Toleranzia

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Redesigning Clinical Trials for Immune Tolerance Therapies: Enhancing Safety, Efficacy, and Regulatory Compliance 12:00 pm

• Uncovering the limitations of autoimmune disease models in the context of the maturity of the autoimmune response in mice compared with humans • Addressing the regulatory hurdles involved in using a biologic and a chemical component in ASIT therapies • Looking at the potential for a changing paradigm in clinical development for precision medicine…Read more

day: Conference Day One

Targeting Myasthenia Gravis with Antigen-Specific Immune Tolerance Approaches for a Durable, Disease Modifying Treatment 10:30 am

• Inducing immune tolerance in MG disease patients with a nanoparticle-based immune tolerizing therapy encapsulating gliadin proteins • Delving into the design of clinical trials for efficacy – considering the interplay of accurate disease modeling and good standard of care with administering a tolerizing therapy • Assessing the durability and necessary dosage to induce immune…Read more

day: Conference Day One